PublicationsSearch by:Platform- Dolasynthen (12)
- Immunosynthen (18)
- Other (40)
Program- XMT-2056 (8)
- XMT-1660 (4)
- Other (45)
Year- 2024
- 2023
- 2022
- 2021
- 2020
- 2019
- 2018
- 2017
- 2016
- 2015
- 2014
- 2013
Platform
- Dolasynthen (12)
- Immunosynthen (18)
- Other (40)
Program
- XMT-2056 (8)
- XMT-1660 (4)
- Other (45)
Year
- 2024
- 2023
- 2022
- 2021
- 2020
- 2019
- 2018
- 2017
- 2016
- 2015
- 2014
- 2013
XMT-2056, a HER2-Targeted Immunosynthen Sting Agonist Antibody-Drug Conjugate, Induces Anti-tumor Activity at Low Doses in Preclinical Models
Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting
November, 2024
Learnings from Translational and Clinical Development of Dolaflexin and Dolasynthen ADCs
World ADC Summit 2024
November, 2024
UPGRADE: Phase 1 Trial of the NaPi2b‑Directed Dolaflexin Antibody‑Drug Conjugate UpRi in Combination With Carboplatin in Patients With Platinum‑Sensitive Ovarian Cancer (PSOC)
International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting
October, 2024
Tumor Cell-Directed STING Agonist Antibody Drug Conjugates Induce Type III Interferons and Anti-Tumor Innate Immune Responses
Nature Communications
July, 2024
The Impact of Scaffold, Linker, Homogeneity and Payload Selection on the Efficacy and Tolerability of Anti-Tubulin ADCs
American Association for Cancer Research Annual Meeting 2024
April, 2024
Results From the Phase 1 Dose Escalation Study of XMT‑1592, a NaPi2b‑Directed Dolasynthen ADC
European Society of Gynaecological Oncology (ESGO) 2024 Congress
March, 2024
UPLIFT: Results from the Phase 2 Trial of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-Directed Dolaflexin ADC in Platinum-Resistant Ovarian Cancer
European Society of Gynaecological Oncology (ESGO) 2024 Congress
March, 2024
Site-Specific Dolasynthen Antibody-Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles Across a Wide Range of Drug to Antibody Ratios
Molecular Cancer Therapeutics, a Journal of the American Association for Cancer Research (AACR)
October, 2023
Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates
Journal of Medicinal Chemistry
July, 2023
Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer
Molecular Cancer Therapeutics, a Journal of the American Association for Cancer Research (AACR)
June, 2023
UPGRADE-A: Phase 1 Expansion Trial of the NaPi2b-Directed Antibody Drug Conjugate Upifitamab Rilsodotin in Combination With Carboplatin in Patients With High-Grade Serous Ovarian Cancer
American Society of Clinical Oncology (ASCO)
June, 2023
Correlating Expression of NaPi2b and Folate Receptor Alpha (FRα) in High‑Grade Serous Ovarian Cancer (HGSOC)
American Society of Clinical Oncology (ASCO)
June, 2023
UP‑NEXT (GOG‑3049/ENGOT‑ov71‑NSGO‑CTU): A Study of Upifitamab Rilsodotin (UpRi), a NaPi2b‑directed Antibody‑Drug Conjugate in Platinum‑Sensitive Recurrent Ovarian Cancer
American Society of Clinical Oncology (ASCO)
June, 2023
Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients with Platinum Resistance
JAMA Oncology
April, 2023
XMT-2056, a HER2-Directed STING Agonist Antibody-Drug Conjugate, Exhibits ADCC Function that Synergizes with STING Pathway Activation and Contributes to Anti-tumor Responses
American Association for Cancer Research (AACR)
April, 2023
The Evolving Landscape of Antibody-Drug Conjugates in Gynecologic Cancers
Cancer Treatment Reviews
April, 2023
NaPi2b Expression in High-Grade Serous Ovarian Cancer: Results From Combined Data Sets
ESMO Gynaecological Cancers Congress 2023
February, 2023
Archival vs Fresh Tumor Samples for Assessing the Gene Expression of NaPi2b and Immune-Related Genes in the Phase 1 Study of Upifitamab Rilsodotin (UpRi) in Platinum-Resistant Ovarian Cancer
34th EORTC-NCI-AACR Symposium
October, 2022
UP-NEXT (GOG-3049/ENGOT-ov71-NSGO-CTU): A Study of Upifitamab Rilsodotin (UpRi), a NaPi2b-directed Antibody-Drug Conjugate (ADC) in Platinum-Sensitive Recurrent Ovarian Cancer
International Gynecologic Cancer Society (IGCS)
September, 2022
UPGRADE: Phase 1 Combination Trial of the NaPi2b-directed Antibody-Drug Conjugate (ADC) Upifitamab Rilsodotin (UpRi; XMT-1536) in Patients With Ovarian Cancer
International Gynecologic Cancer Society (IGCS)
September, 2022
UPLIFT (ENGOT-ov67/GOG-3048): A Pivotal Cohort of the XMT-1536-1 Trial of Upifitamab Rilsodotin (XMT-1536; UpRi), a NaPi2b-directed Antibody-Drug Conjugate (ADC), in Platinum-Resistant Ovarian Cancer
International Gynecologic Cancer Society (IGCS)
September, 2022
Comparison of NaPi2b Expression From Paired Tissue Samples in a Clinical Study of Upifitamab Rilsodotin (UpRi; XMT-1536) Supports a Strategy of Testing in Archival Material
International Gynecologic Cancer Society (IGCS)
September, 2022
Evaluation of NaPi2b Expression in a Well-Annotated Longitudinal Tissue Series of Ovarian Serous Carcinomas
International Gynecologic Cancer Society (IGCS)
September, 2022
XMT-2056: A HER-2 Targeted Immunosynthen STING Agonist Antibody Drug Conjugate
World ADC Summit 2022
September, 2022
XMT-2056: A HER-2 Targeted Immunosynthen STING Agonist Antibody Drug Conjugate
Society for Immunotherapy of Cancer (SITC)
August, 2022
XMT-2056, a HER2-Targeted Immunosynthen STING-Agonist Antibody-Drug Conjugate, Binds a Novel Epitope of HER2 and Shows Increased Anti-tumor Activity in Combination With Trastuzumab and Pertuzumab
American Association for Cancer Research (AACR)
April, 2022
Tumor Cell-Targeted STING-Agonist Antibody-Drug Conjugates Achieve Potential Anti-tumor Activity by Delivering STING Agonist Specifically to Tumor Cells and FcγRi-Expressing Subset of Myeloid Cells
American Association for Cancer Research (AACR)
April, 2022
Anti-tumor Effect of XMT-1660, a B7-H4 Targeting Antibody Drug Conjugate, in an Unselected Panel of Patient Derived Xenograft Models of Breast Cancer
American Association for Cancer Research (AACR)
April, 2022
Optimizing the Dose of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC): Updated Analysis of a Phase 1b Expansion Study in Ovarian Cancer
SGO 2022 Annual Meeting on Women’s Cancer
March, 2022
Uplift (Engot-OV67/Gog-3048): A Pivotal Cohort of Upifitamab Rilsodotin (XMT-1536; UpRi), an Napi2B-Directed Dolaflexin Antibody Drug Conjugate (ADC) In Platinum-Resistant Ovarian Cancer
SGO 2022 Annual Meeting on Women’s Cancer
March, 2022
Updated Results From the Phase 1b Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer
SGO 2022 Annual Meeting on Women’s Cancer
March, 2022
UPGRADE: Phase 1 Combination Trial of the NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) Upifitamab Rilsodotin (UpRi; XMT-1536) in Patients With Ovarian Cancer
SGO 2022 Annual Meeting on Women’s Cancer
March, 2022
Development of a Novel CDx IHC Assay on the BOND-III to detect NaPi2b in Serous Ovarian Cancer Samples to Identify Patients Eligible for Treatment with Upifitamab Rilsodotin (UpRi)
USCAP 2022 Annual Meeting
March, 2022
STING-Agonist ADCs Targeting Tumor-Associated Antigens Coordinate Immune-Mediated Killing of Antigen-Negative Cancer Cells
Society for Immunotherapy of Cancer (SITC)
November, 2021
Site Specific Dolasynthen ADCs Demonstrate Consistent Exposure Across a Wide Range of Drug-To-Antibody Ratios
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October, 2021
XMT-2056: Tumor-targeted Innate Immune Activation via a STING-agonist Antibody Drug Conjugate
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October, 2021
Interim Data from the Ovarian Cancer Expansion Cohort and Next Steps for UpRi Development Plan
Company Presentation
September, 2021
XMT-1660, a B7-H4-Targeted Dolasynthen Antibody-Drug Conjugate for the Treatment of Breast Cancer
American Association for Cancer Research (AACR)
April, 2021
XMT-2056, a Well-Tolerated, Immunosynthen-Based STING-Agonist Antibody-Drug Conjugate Which Induces Anti-tumor Immune Activity
American Association for Cancer Research (AACR)
April, 2021
Tumor Cell-intrinsic STING Pathway Activation Leads to Robust Induction of Type III Interferons and Contributes to the Anti-tumor Activity Elicited by STING Agonism
American Association for Cancer Research (AACR)
April, 2021
Dolaflexin: A Novel Antibody-Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect
Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research (AACR)
March, 2021
The Dolaflexin-based Antibody-Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b
Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research (AACR)
March, 2021
Tumor Cell-intrinsic STING Pathway is Activated in the Presence of Cues from Immune Cells and Contributes to the Anti-tumor Activity of Tumor Cell-targeted STING Agonist Antibody-Drug Conjugates
Society for Immunotherapy of Cancer (SITC)
November, 2020
Safety and Efficacy of XMT-1536 in Ovarian Cancer: A Subgroup Analysis from the Phase 1 Expansion Study of XMT-1536, a NaPi2b Antibody-Drug Conjugate
European Society of Medical Oncology (ESMO)
September, 2020
Tumor Targeting of a STING Agonist by Means of an Antibody-Drug Conjugate Induces Potent Anti-Tumor Immune Responses
Innate Immunity Stimulating Therapies Summit
July, 2020
Systemic Administration of STING Agonist Antibody-Drug Conjugates Elicit Potent Anti-Tumor Immune Responses with Minimal Induction of Circulating Cytokines
American Association for Cancer Research (AACR)
June, 2020
XMT-1592, a Site-Specific Dolasynthen-Based NaPi2b-Targeted Antibody-Drug Conjugate for the Treatment of Ovarian Cancer and Lung Adenocarcinoma
American Association for Cancer Research (AACR)
June, 2020
Phase 1 Expansion Study of XMT-1536, a Novel NaPi2b-targeting Antibody-Drug Conjugate (ADC): Preliminary Efficacy, Safety, and Biomarker Results in Patients with Previously Treated Metastatic Ovarian Cancer (OC) or Non-Small Cell Lung Cancer (NSCLC)
American Society of Clinical Oncology (ASCO)
May, 2020
A Phase 1 Study of XMT-1536 in Patients With Solid Tumors Likely to Express NaPi2B: A Summary of Dose Escalation
SGO 2020 Annual Meeting on Women’s Cancer
May, 2020
Tumor Targeting of a STING Agonist With an Antibody Drug Conjugate Elicits Potent Anti-tumor Immune Responses
Society for Immunotherapy of Cancer (SITC)
November, 2019
NaPi2b Expression in a Large Surgical Non-Small Cell Lung Cancer (NSCLC) Cohort
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October, 2019
Simultaneous Quantification of Total Antibody and Antibody-Conjugated Drug for XMT-1522 in Human Plasma Using Immunocapture-Liquid Chromatography/Mass Spectrometry
Journal of Pharmaceutical and Biomedical Analysis, Volume 174, 10 September 2019, Pages 441-449
September, 2019
Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b
American Society of Clinical Oncology (ASCO)
June, 2019
Dolasynthen: A Novel, Homogeneous Auristatin F Hydroxypropyl Amide Antibody-Drug Conjugate Platform
American Association for Cancer Research (AACR)
April, 2019
An Antibody-Drug Conjugate Carrying a Microtubule Inhibitor and a DNA Alkylator Exerts Both Mechanisms of Action on Tumor Cells
American Association for Cancer Research (AACR)
March, 2019
Target Expression/Efficacy Relationship of XMT-1522, a HER2-targeting Antibody Drug Conjugate (ADC), in an Unselected Series of Non-small Cell Lung Cancer (NSCLC) Primary Human Carcinoma Xenografts
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
November, 2018
Discovery of the Novel, Homogeneous Payload Platform Dolasynthen for Antibody-Drug Conjugates
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
November, 2018
Indole-Biaryl Pyrrolobenzodiazepines (I-BiPs): A Potent and Well-tolerated Class of DNA Mono-alkylating Payload for Antibody-Drug Conjugates (ADCs)
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
November, 2018
MERS67 is a Novel anti-NaPi2b Antibody and Demonstrates Differential Expression Patterns in Lung Cancer Histologic Subtypes
International Association for the Study of Lung Cancer (IASLC)
September, 2018
Phase 1 Dose Escalation of XMT-1522, a Novel HER2-targeting Antibody-Drug Conjugate (ADC), in Patients with HER2-expressing Breast, Lung and Gastric Cancer
American Society of Clinical Oncology (ASCO)
June, 2018
Unique Pharmacological Properties of Dolaflexin-Based ADCs – A Controlled Bystander Effect
American Association for Cancer Research (AACR)
April, 2018
Synergy of an Anti-HER2 ADC TAK-522 (XMT-1522) in Combination with Anti-PD1 mAb in a Syngeneic Breast Cancer Model Expressing Human HER2
American Association for Cancer Research (AACR)
April, 2018
Relationship of Napi2B Expression and Efficacy of XMT-1536, a Napi2B Targeting Antibody Drug Conjugate (ADC), in an Unselected Panel of Human Primary Ovarian Mouse Xenograft Models
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October, 2017
A Phase Ib, First-In-Human, Dose Escalation and Expansion Study of XMT-1522, a Novel Antibody-Drug Conjugate (ADC) Directed Against HER2, in Patients With Advanced Breast Cancer and Other Advanced Tumors Expressing HER2
June, 2017
Non-clinical Pharmacokinetics of XMT-1522, a HER2 Targeting Auristatin-based Antibody Drug Conjugate
April, 2017
Combination of Anti-HER2 ADC XMT-1522 and Checkpoint Inhibitor Pembrolizumab for Treatment of NSCLC in Preclinical Models
April, 2017
A NaPi2b Antibody-Drug Conjugate Induces Durable Complete Tumor Regressions in Patient-Derived Xenograft Models of NSCLC
December, 2016
Discovery and Preclinical Development of a Highly Potent NaPi2b-Targeted Antibody-Drug Conjugate (ADC) With Significant Activity in Patient-Derived Non-small Cell Lung Cancer (NSCLC) Xenograft Models
April, 2016
Optimization of Lead Antibody Selection for XMT-1522, a Novel, Highly Potent HER2-Targeted Antibody-Drug Conjugate (ADC)
April, 2016
XMT-1522 Induces Tumor Regressions in Pre-clinical Models Representing HER2-Positive and HER2 Low-Expressing Breast Cancer
December, 2015
A Polymer-Based Antibody–Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy
June, 2015
A Novel, Highly Potent HER2-Targeted Antibody-Drug Conjugate (ADC) For the Treatment of Low HER2-Expressing Tumors and Combination With Trastuzumab-Based Regimens in HER2-Driven Tumors
April, 2015
Trastuzumab-Dolaflexin, a Highly Potent Fleximer-Based Antibody-Drug Conjugate, Demonstrates a Favorable Therapeutic Index in Exploratory Toxicology Studies in Multiple Species
April, 2015